Prescription drugs boosts Johnson & Johnson forecasts
Johnson & Johnson raised its full-year earnings forecast as it reported higher third-quarter sales of psoriasis treatment Stelara and cancer drug Imbruvica while attempting to alleviate investor concerns over mounting legal challenges.